Unique ID issued by UMIN | UMIN000015794 |
---|---|
Receipt number | R000018380 |
Scientific Title | Efficacy of monthly sodium risedronate for the treatment of corticosteroid induced osteoporosis in patients with rheumatoid arthritis (multicenter, double-blind, randomized, placebo-controlled, parallel-group study ) |
Date of disclosure of the study information | 2014/12/10 |
Last modified on | 2018/03/12 11:03:33 |
Efficacy of monthly sodium risedronate for the treatment of corticosteroid induced osteoporosis in patients with rheumatoid arthritis (multicenter, double-blind, randomized, placebo-controlled, parallel-group study )
RISOTTO
(sodium RISedrOnate for sTeroid induced osTeOporosis with rheumatoid arthritis)
Efficacy of monthly sodium risedronate for the treatment of corticosteroid induced osteoporosis in patients with rheumatoid arthritis (multicenter, double-blind, randomized, placebo-controlled, parallel-group study )
RISOTTO
(sodium RISedrOnate for sTeroid induced osTeOporosis with rheumatoid arthritis)
Japan |
osteoporosis, rheumatoid arthritis
Clinical immunology |
Others
NO
To investigate the efficacy of monthly sodium risedronate for the treatment of coricosteroid induced osteoporosis in patients with rheumatoid arthritis
Efficacy
Phase IV
Percentage change from baseline in the bone mineral density of lumbar spine (L2-4) at 6 months
Percentage change from baseline in the bone mineral density of femoral neck and total hip at 6 months
Incidence of vertebral fractures at 6 months
Change from baseline in bone metabolic markers such as TRACP-5b and BAP at 6 months
Change from baseline in disease activity score 28 (DAS28) at 6 months
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
YES
Central registration
2
Treatment
Medicine |
monthly risedronate sodium 75mg for 6 months
monthly placebo for 6 months
20 | years-old | <= |
Not applicable |
Male and Female
Rheumatoid arthritis patients with osoteoporosis receiving corticosteroid for more than 3 months.
In addition, patients who have more than 3 in the risk factor scores in Japanese guideline for the management and treatment in patients with corticosteroid induced osteoporosis.
Patients who received drugs for osteoporosis within 2 months at inclusion of the study except alphacalcidol and calcitriol
Patients who had received bisphosphonates
Patients who had undergone the operation of lumbar spine
Patients who have a severe decayed tooth to be treated
Patients who are considered to be contraindicated for bisphosphonates
Patients who are thought to be inappropriate for this study by physicians
165
1st name | |
Middle name | |
Last name | Tatsuya Atsumi |
Hokkaido University Graduate School of Medicine
Division of rheumatology, endcrinology and nephrology
N15, W7, Kita-ku, Sapporo, Hokkaido, Japan
011-706-5915
at3tat@med.hokudai.ac.jp
1st name | |
Middle name | |
Last name | Nao Horie |
Hokkaido University Hospital
Clinical Research and Medical Innovation Center
N14, W5, Kita-ku, Sapporo, Hokkaido, Japan
011-706-7735
http://trctca.huhp.hokudai.ac.jp/
nhorie@med.hokudai.ac.jp
Division of rheumatology, endcrinology and nephrology, Hokkaido University Graduate School of Medicine
Eisai Co, Ltd
Profit organization
NO
2014 | Year | 12 | Month | 10 | Day |
Unpublished
No longer recruiting
2014 | Year | 12 | Month | 01 | Day |
2014 | Year | 12 | Month | 15 | Day |
2018 | Year | 01 | Month | 31 | Day |
2018 | Year | 04 | Month | 20 | Day |
2018 | Year | 04 | Month | 30 | Day |
2018 | Year | 06 | Month | 30 | Day |
2014 | Year | 11 | Month | 30 | Day |
2018 | Year | 03 | Month | 12 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018380